Lilly links COVID-19 antibody to reduced hospitalization rate After axing leading program, Unity now takes the ax to staff Graphite Bio debuts with $45M to cure sickle cell disease using gene edits Sponsored: Fierce Innovation Awards — Life Sciences Edition 2020: Winners Announcement! Cygnal Therapeutics nabs Merck, Takeda vet Wagner for CMO AstraZeneca's COVID-19 vaccine adverse event has NIH 'very concerned' Defining COVID-19 immunity: CDC, EU researchers tap Siemens Healthineers to help standardize antibody tests Tiny biologic drug to fight COVID-19 shows promise in animal models Featured Story | By Nick Paul Taylor Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients recently diagnosed with mild to moderate cases of COVID-19. However, two of the three doses, including the highest studied in the phase 2 trial, failed to beat placebo in terms of reducing viral load by Day 11. read more |
| |
|---|
|
| | Sterile Filling with Eurofins Eurofins BioPharma Product Testing can help eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 trials using our state-of-the-art vial filler. Learn More. |
Top Stories By Ben Adams A month ago, trendy anti-aging biotech Unity Biotechnology cut its leading and only clinical drug after a major flop, reverting it back to a preclinical biotech. read more By Amy Sokolow The biggest challenge for scientists working on genome engineering, according to Josh Lehrer, M.D., is targeting DNA at a specific location and inserting new, corrected genetic material. Lehrer’s company, Graphite Bio, is looking to change that with gene-editing technology that doesn’t just “cut” genes, but also “pastes” templates that fix the underlying issue in the patient’s DNA. read more Sponsored by: Fierce Biotech The Fierce Innovation Awards: Life Sciences Edition have come to a close and we're pleased to announce the 2020 award winners! read more By Amirah Al Idrus A year after its official debut, Cygnal Therapeutics is signing a chief medical officer to translate its exoneural approach into treatments for cancer and other diseases. John Wagner, M.D., Ph.D., joins from Foresite Capital, where he was a venture partner, bringing experience in early development and translational medicine from his time at Merck and Takeda. read more By Nick Paul Taylor Leaders at the National Institutes of Health are “very concerned” about the adverse event that led AstraZeneca to pause its COVID-19 vaccine clinical trial, according to the intramural clinical director at one of its divisions. read more By Conor Hale The project will help define the proper concentrations of antibodies necessary for a test to determine whether a person is immune to COVID-19. read more By Angus Liu A research team led by the University of Pittsburgh School of Medicine has identified an antibody component that’s 10 times smaller than a full-sized antibody. They constructed a drug with it and found it to be effective in preventing and treating SARS-CoV-2 in rodent models. Its small size might make it amenable to inhaled formulations. read more | | LabConnect is now offering global analytical and operational services to meet your COVID-19 testing requirements. We offer viral load testing by RT-qPCR and multiple COVID-19 screening assays. Connect with LabConnect today. We are here to help. |
Resources Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Medtech Innovation Week October 19-22 Become Fluent In Drug Development With Our Industry Expert October 21-22, 2020 | 9am - 3:30pm ET Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 